Introduction {#j_jomb-2018-0038_s_001}
============

Among pediatric malignancies, acute lymphoblastic leukemia (ALL) is the most common hematological and overall malignancy, contributing to 30% of diagnosed cancers and around 80% of all pediatric leukemias. Pediatric ALL is a malignancy with one of the highest cure rates, achieved by treating the patients with the internationally recognised treatment protocols like the Berlin-Frankfurt-Munster (BFM) protocol ([@j_jomb-2018-0038_ref_001], [@j_jomb-2018-0038_ref_002], [@j_jomb-2018-0038_ref_003]). Risk stratification of ALL is para mount in choosing the effective treatment strategy. Hence, risk stratification is already performed on the day of diagnosis according to the BFM protocol, as well as on other well-defined checkpoints, leading to adjustment of the therapy protocol accordingly.

The first part of the BFM protocol is the remission induction therapy. This phase lasts for 39 days, and its goal is to lower a number of lymphoblasts in the bone marrow and peripheral blood. There are three check points during the course of the remission induction therapy phase: day 8, day 15 and day 33. On day 8 of treatment, blast concentration in peripheral blood is measured, and a patient is put in the high-risk category if the number of blasts remains above 1000 per μL. Percentage of blasts in bone marrow on day 15 and 33 is also used for risk stratification, as a way of measuring the minimal residual disease (MRD). In the remission induction therapy, the patient is administered with prednisone, vincristine, daunorubicin, L-asparaginase and methotrexate intrathecally. Prednisone, a synthetic glucocorticoid (GC), is administrated throughout the remission induction therapy phase, and during the first 8 days, it is the only systemically administered therapeutic.

GCs are commonly used for the treatment of inflammatory, autoimmune diseases, pediatric leukemia and after transplantation ([@j_jomb-2018-0038_ref_004]). GCs are drugs which act through binding to the glucocorticoid receptor (GR) ([@j_jomb-2018-0038_ref_005]). GCs, when bound to the ligand binding domain (LBD) of GR, activate GR, the receptor dimerises and, through binding to the GC responsive elements in DNA, upregulate the expression of anti-inflammatory proteins, like lipocortin-1 and IκBα. On the other hand, it downregulates the expression of numerous cytokines, like IL-2, IL-4, IL-6, IL-10, etc. ([@j_jomb-2018-0038_ref_006]). GCs can also affect inflammation by binding to a key transcription factor in immune response and cytokine production, NF-κB, thus preventing immune response stimulation ([@j_jomb-2018-0038_ref_007]). Last, but not the least, GCs inhibit proliferation and promote apoptosis in immune cells ([@j_jomb-2018-0038_ref_008]). Due to these effects, GCs are essential in the remission induction therapy of any ALL protocol, since they are the most important drugs in lowering the number of lymphoblasts ([@j_jomb-2018-0038_ref_009]).

Even though the cure rate of ALL in childhood is high, around 15--20% of patients experience relapse which often leads to the lethal outcome ([@j_jomb-2018-0038_ref_010]). The mechanisms which contribute to an unfavourable outcome are still unclear. Implementation of pharmacogenomics in the treatment protocol could provide a solution to this problem, through therapy individualisation. Indeed, certain genetic variants are already used to guide therapy regimes of drugs used in ALL treatment. Recently, the expression level of certain RNAs has been associated with drug response, which means that measuring RNA expression could be used as a marker of drug response and could even guide therapy individualisation. If enough evidence is gathered for such RNAs, alongside pharmacogenetic markers, pharmacotranscription markers could also emerge.

Most of the genome contains transcripts which do not translate into proteins, the non-coding RNAs (ncRNAs). It was shown that there are significant interindividual differences in ncRNA expression and that some of them are involved in drug response ([@j_jomb-2018-0038_ref_011]). Pharmacotranscriptomics is a field which aims to create an adequate therapy for individuals based on transcriptome variations. When considering the transcriptome, numerous ncRNAs have shown to have aberrant expression or deregulation in diabetes ([@j_jomb-2018-0038_ref_012]), cancer ([@j_jomb-2018-0038_ref_013], [@j_jomb-2018-0038_ref_014], [@j_jomb-2018-0038_ref_015]) and other diseases. It has also been reported that ncRNAs are deregulated in leukemia ([@j_jomb-2018-0038_ref_016], [@j_jomb-2018-0038_ref_017], [@j_jomb-2018-0038_ref_018]). However, further inquiry into the role of ncRNAs in pediatric ALL is required.

Growth arrest-specific 5 (*GAS5*) is a long (more than 200 base pairs) non-coding RNA (lncRNA), which promotes apoptosis and halts the cell-cycle in T lymphocytes ([@j_jomb-2018-0038_ref_008]). Apart from its functional role as a growth arrest factor, *GAS5* also imitates the glucocorticoid response element (GRE), a DNA sequence which is recognised by the DNA binding domain (DBD) of GR, acting as a decoy for GR, thus inhibiting GR's actions ([@j_jomb-2018-0038_ref_019]). Thus, *GAS5* is a possible prognostic and pharmacotranscription marker in childhood ALL.

Previously, *GAS5* was studied in breast cancer ([@j_jomb-2018-0038_ref_014]), where its downregulation contributed to tumour growth and poor survival of patients. *GAS5* was found deregulated in prostate cancer, and the cancer cells have shown an upregulation of *GAS5*, as well as resistance to androgen treatment ([@j_jomb-2018-0038_ref_020]). In pancreatic cancer, *GAS5* was also downregulated ([@j_jomb-2018-0038_ref_021]). When it came to the pharmacotranscriptomic role of *GAS5* in GC treatment, *GAS5* was only studied in pediatric patients with inflammatory bowel disease (IBD) ([@j_jomb-2018-0038_ref_022]). In this study, *GAS5* is recommended to be considered as a pharmacotranscription marker in pediatric IBD treatment. The pharmacotranscriptomic potential of *GAS5* has not been studied in the context of pediatric leukemia.

The aim of this study is to provide an insight into the correlation between *GAS5* expression levels and the clinical response of treatment during remission induction therapy phase in childhood ALL. We have measured *GAS5* expression at three checkpoints of BFM protocol (at diagnosis, days 15 and 33), and correlated it with therapy response evaluated using BFM protocol parameters. In order to better characterise therapy response on day 8, we carried out additional analysis in which the cut-off value for therapy response was 100 blasts per μL in peripheral blood.

Materials and Methods {#j_jomb-2018-0038_s_002}
=====================

Subjects {#j_jomb-2018-0038_s_002_s_001}
--------

Peripheral blood samples (n = 29) have been gathered from ALL pediatric patients from the University Children's Hospital in Belgrade at diagnosis (day 0), on day 15 and day 33 of the remission induction therapy. The patients were diagnosed, stratified into risk groups and treated according to Berlin-Frankfurt-Munster protocols: BFM ALL IC-2002 and BFM ALL IC-2009. The therapy regimes of these two protocols did not differ throughout the remission induction therapy. Approval by the Ethics Committee of the University Children's Hospital, University of Belgrade was obtained. Informed consent was obtained from each patient or patient's parent or guardian. The principles of the Declaration of Helsinki were honoured during the entirety of the study's course.

RNA isolation {#j_jomb-2018-0038_s_002_s_002}
-------------

Mononuclear cells were isolated from peripheral blood samples of childhood ALL patients using Ficoll-Paque Plus solution (GE Healthcare, Buckinghamshire, UK) and stored in TRI reagent solution (Ambion, TX, USA) at -80 °C. Total RNA was subsequently isolated according to manufacturer's instruction and stored at -80 °C.

Measuring of GAS5 expression level {#j_jomb-2018-0038_s_002_s_003}
----------------------------------

The level of *GAS5* expression was assessed relative to *GAPDH* expression using the 2^-ΔΔCt^ method. Normalised, median expression level before therapy was used as a calibrator to adjust the expression values of the other samples. To measure *GAS5* expression relative to *GAPDH* expression, Hs03464472_m1 and Hs99999905_m1 Taqman gene expression assays were used (Applied Biosystems, Foster City, CA, USA) as well as KAPA Probe Fast qPCR Master Mix (Kapa Biosystems, MA, USA) on 7900HT Fast Real-Time PCR machine.

Statistical analysis {#j_jomb-2018-0038_s_002_s_004}
--------------------

When analysing the correlation between continuous variables, the Spearman correlation coefficient was used (ρ). To measure the difference in *GAS5* expression between different time points, Wilcoxon sign rank test was used. Association of clinical parameters of ALL patients and *GAS5* expression level was assessed using the Mann-Whitney U test. The cut-off value of p=0.05 for statistical significance has been chosen. The SPSS software (IBM SPSS Statistics v.21) was the tool of choice for statistical analysis.

Results {#j_jomb-2018-0038_s_003}
=======

Demographic and clinical characteristics of childhood ALL patients at diagnosis {#j_jomb-2018-0038_s_003_s_001}
-------------------------------------------------------------------------------

Our sample contained 29 childhood ALL patients. There were 14 male patients (48.3%). The median age was 6.0 (interquartile range: 3.0--12.4) years. B-cell leukemia was present in 26 (89.65%) patients, while the rest were diagnosed with T-cell leukemia.

Expression of GAS5 at diagnosis, on day 15 and day 33 of remission induction therapy {#j_jomb-2018-0038_s_003_s_002}
------------------------------------------------------------------------------------

First, we considered the level of *GAS5* expression at diagnosis, on day 15 and day 33 irrespective of clinical characteristics of ALL patients. There were noted interindividual differences of *GAS5* expression level among patients. Namely, at diagnosis, the median *GAS5* expression level was 1.00 (interquartile

range 0.66--1.56). On day 15, the median *GAS5* expression level was 6.94 (interquartile range 4.91--9.40). On day 33, the median *GAS5* expression level was 1.75 (interquartile range 0.74--4.37).

Our results have shown that for each ALL patient, *GAS5* expression was higher on day 15 in comparison to its level at diagnosis (Wilcoxon sign rank test, p\<0.0005). On day 33, the level of *GAS5* expression decreased for all except 4 patients (Wilcoxon sign rank test, p\<0.0005). Still, the level of *GAS5* expression on day 33 was higher than at diagnosis for the majority of patients (Wilcoxon sign rank test, p=0.001) (*[Figure 1](#j_jomb-2018-0038_fig_001){ref-type="fig"}*).

![Relative GAS5 expression measured in mononuclear cells at diagnosis (day 0), on day 15 and day 33 in 29 ALL patients. Each grey line connects relative GAS5 expression measured in one ALL patient. Dark horizontal lines denote median values of relative GAS5 expression at each time point.](jomb-38-292-g001){#j_jomb-2018-0038_fig_001}

As stated above, the level of *GAS5* expression increased between day 15 and day 33 of the treatment for 4 patients only. We further analysed this result by comparing the clinical and demographic characteristics of this subgroup of patients with the rest of ALL patients. All 4 patients were male, B-cell leukemia and stratified into the high-risk category. Moreover, in this subgroup of 4 patients, there was a higher percentage of blasts in bone marrow on day 15 in comparison to the rest of ALL patients (Mann-Whitney test, p=0.051).

No correlation was observed between age or gender and the level of *GAS5* expression at any time point of therapy.

Correlation of GAS5 expression with clinical characteristics of patients before therapy {#j_jomb-2018-0038_s_003_s_003}
---------------------------------------------------------------------------------------

We analysed the correlation of *GAS5* expression and patients' clinical parameters before therapy. The number of leukocytes per μL of peripheral blood on the day of diagnosis is important for prognosis and further treatment considerations. Our results showed a statistical trend towards a negative correlation between the level of *GAS5* expression at diagnosis and the number of leucocytes per μL of peripheral blood at diagnosis (Spearman's correlation, p=0.069, ρ=-0.342).

Correlation between GAS5 expression levels at diagnosis and on days 15 and 33 and response to therapy {#j_jomb-2018-0038_s_003_s_004}
-----------------------------------------------------------------------------------------------------

We considered the level of *GAS5* expression at diagnosis in correlation with clinical parameters indicative of therapy response. The lower number of blasts (below 100 per μL of peripheral blood) on day 8 of therapy was associated with higher *GAS5* levels at diagnosis (Mann-Whitney test, p=0.016, *[Figure 2](#j_jomb-2018-0038_fig_002){ref-type="fig"}*).

![Boxplot chart showing relative expression level of GAS5 in patients' mononuclear cells on the day of diagnosis in patients with an absolute number of blasts per μL of peripheral blood on day 8 below 100 and no less than 100 (Mann-Whitney test, p=0.016).](jomb-38-292-g002){#j_jomb-2018-0038_fig_002}

We also considered the ratio between the expression levels of *GAS5* on day 15 and at diagnosis. ALL patients had a significantly higher ratio when the number of blasts on day 8 of therapy was above 100 (Mann-Whitney test, p = 0.009, *[Figure 3](#j_jomb-2018-0038_fig_003){ref-type="fig"}*).

![Boxplot chart showing the ratio of GAS5 expression in patients' mononuclear cells on day 15 and at diagnosis in patients with an absolute number of blasts per μL of peripheral blood on day 8 below 100 and no less than 100 (Mann-Whitney test, p=0.009).](jomb-38-292-g003){#j_jomb-2018-0038_fig_003}

Expression of *GAS5* at any time point was not associated with MRD on day 15 or 33 of remission induction therapy.

Discussion {#j_jomb-2018-0038_s_004}
==========

Among transcriptomic markers of hematological malignancies, lncRNA *GAS5* has come to the special attention of researchers and medical practitioners.

There is sporadic data on the expression of *GAS5* in hematological malignancies. It was found that *GAS5* was overexpressed in pediatric B-cell precursor acute lymphoblastic leukemia, specifically in high hyperdiploid (HeH) and t(1;19)(q23;p13)-positive cases ([@j_jomb-2018-0038_ref_023]). However, it is essential to underline that *GAS5* gene is located on chromosome 1q and that its increased expression level could be a consequence of a gene dosage effect in subtypes of childhood ALL characterised by a gain of 1q through duplication or an unbalanced translocation.

In another study, the influence of *GAS5* rs55829688 (T \> C) variant on *GAS5* expression in peripheral blood mononuclear cells (PBMC) of acute myeloid leukemia patients was demonstrated. *GAS5* rs55829688 CC genotype showed increased *GAS5* expression ([@j_jomb-2018-0038_ref_024]).

This is the first study that analysed the correlation between *GAS5* expression and therapy response in childhood ALL. We have observed that *GAS5* expression levels were GC treatment-dependent. More precisely, we have detected an increased level of expression of *GAS5* on day 15 (continuous administration of GCs) compared to the day before the GC therapy started. We have also detected that the level of *GAS5* expression significantly decreased on day 33 (GC dose significantly reduced). Changes in the expression level of *GAS5* according to the dosage of GCs were observed previously in HeLa and LoVo cells ([@j_jomb-2018-0038_ref_022]). Although both untreated Hela (human cervical carcinoma) and LoVo (colorectal cancer) cell lines had similar *GAS5* expression levels, upregulation of *GAS5* was observed in LoVo cell line after GC treatment, while in HeLa cells a downregulation was detected ([@j_jomb-2018-0038_ref_022]). It is evident that the expression of *GAS5* is not the same in different tissues or diseases ([@j_jomb-2018-0038_ref_025]). Since we have studied *GAS5* expression in PBMC, we aimed to compare our results with similar ones. There are limited reports on *GAS5* expression in PBMC treated with GCs. One of them was *in vitro* study of *GAS5* expression in PBMC of healthy blood donors treated with GCs, in which interindividual differences were reported ([@j_jomb-2018-0038_ref_026]).

Interestingly, our results indicated that in all childhood ALL patients, *GAS5* expression was increased after administration of GCs. It is known that GCs induce apoptosis in lymphoid cells ([@j_jomb-2018-0038_ref_027]) through the signalling pathway in which the cellular inhibitor of apoptosis 2 (cIAP2) is involved ([@j_jomb-2018-0038_ref_028], [@j_jomb-2018-0038_ref_029], [@j_jomb-2018-0038_ref_030]). Overexpression of cIAP2 results in inhibition of apoptosis. The *cIAP2* gene promoter contains GREs to which GR binds and activates the gene's transcription ([@j_jomb-2018-0038_ref_028], [@j_jomb-2018-0038_ref_029]). It has been shown that *GAS5* hampers GR binding to cIAP2's GREs, thus preventing cIAP2's transcription ([@j_jomb-2018-0038_ref_031]). The conclusion of this study is that the increased level of *GAS5* is associated with induction of apoptosis. We presume that the increased level of *GAS5* expression in the initial phase of therapy, detected in all patients in our study, reflects the therapeutic effect of GCs on leukemia cells through induction of apoptosis. The signalling path way down-stream from *GAS5* to cell death proteases caspase 3, 7, and 9 has been investigated and relatively elucidated ([@j_jomb-2018-0038_ref_030], [@j_jomb-2018-0038_ref_031], [@j_jomb-2018-0038_ref_032]). However, the upstream part of the pathway, leading from GCs binding to the LBD of GR, to *GAS5*, has not been studied yet. There fore, the molecular mechanism of *GAS5* transcriptional induction by GCs in leukemia cells, detected in our study, needs to be clarified in future.

Besides our attempt to elaborate the mechanism of *GAS5* participation in the GC therapeutic effect, our study also pointed out to the potential role of *GAS5* expression as a pharmacotranscription marker in the remission induction therapy of childhood ALL.

We have observed that the expression level of *GAS5* at diagnosis correlated with the number of leukocytes per μL of peripheral blood. The higher the *GAS5* expression level was, the lower the number of leukocytes was. Additionally, patients with a higher expression level of *GAS5* at diagnosis had a lower number of blasts in peripheral blood on day 8 of therapy. These findings point out the contribution of *GAS5* to apoptosis in leukemia. We propose that *GAS5* expression could be included in the pharmacotranscriptomic algorithm in the initial phase of remission induction therapy of childhood ALL patients since the level of *GAS5* expression predicts GC response on day 8.

On the contrary, we have observed a correlation between the ratio of *GAS5* expression level on day 15/diagnosis and the number of blasts in peripheral blood on day 8. The higher the ratio, the higher the number of blasts, indicating poor therapeutic response associated with an increase of *GAS5* expression in later phases of therapy. A possible mechanism of these clinical manifestation related to *GAS5* is that *GAS5*, imitating GRE, acts as a decoy for GR, binds it and prevents its action ([@j_jomb-2018-0038_ref_019]).

It is difficult to predict the role of *GAS5* in leukemia due to its roles both in apoptosis and cell-cycle arrest ([@j_jomb-2018-0038_ref_008]). Additionally, a dual role of *GAS5* in opposing cellular processes is even more prominent upon GC administration. Therefore, our results suggest that during remission induction therapy of childhood ALL, the antiapoptotic effect of *GAS5*, mediated through its GR-binding, becomes dominant. However, it is necessary to emphasise that in the later course of the remission induction therapy, not only GCs are administered, but also other drugs. The *GAS5* expression may also be influenced by those drugs.

This is the first study of pharmacotranscriptomic potential of *GAS5* in childhood ALL. We find that our study lacks the *GAS5* expression level data on day 8 since that is an important checkpoint of BFM protocol. Further studies on a larger cohort of childhood ALL patients are needed to corroborate our findings.
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